PTC Therapeutics, Inc.
Investor Relations Department
100 Corporate Ct.
South Plainfield, NJ 07080
United States

Visit IR website
Sign-up for Email alerts

NASDAQ: PTCT	
Last Trade:	20.64
Trade Time:	2:31 PM ET Jul 20, 2017
Change:	1.21 (+6.202%)
Day Range	19.80 - 20.89
52-Week Range	4.03 - 19.99
Volume	891,813

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

PTC Therapeutics, Inc. is committed to serving the interests of our shareholders. This part of our website includes corporate governance documents, press releases, financial information and other documents to help shareholders better understand who we are and what we do.

... (more)

Stock Performance

Press Releases [View all]

Jul 18, 2017
PTC Therapeutics Announces Publication of Data from ACT DMD in The Lancet

Jul 1, 2017
Preliminary Phase 2 Data from Spinal Muscular Atrophy Program Presented at CureSMA Conference

Jun 30, 2017
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 22, 2017
New Analyses of Translarna™ (ataluren) Data from ACT DMD Presented at the 12th Annual European Pediatric Neurology Society Congress

Jun 6, 2017
PTC Therapeutics Announces FDA Advisory Committee Meeting for Ataluren for the Treatment of Nonsense Mutation Dystrophinopathy

Financials [View all]

Mar 16, 2017
Annual Report (10-K)

Apr 28, 2017
Proxy Statement (DEF 14A)

May 8, 2017
Quarterly Report (10-Q)

Nov 3, 2016
Quarterly Report (10-Q)

Aug 4, 2016
Quarterly Report (10-Q)